Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms
Freund-Levi Y, Basun H, Cederholm T, Faxén-Irving G, Garlind A, Grut M, Vedin I, Palmblad J, Wahlund LO, Eriksdotter-Jönhagen M
International journal of geriatric psychiatry · 110 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- Alzheimer Society
Según 1 financiador declarado.
Publicación
- Publicado
- 2007-06-21 · Int J Geriatr Psychiatry · vol. 23 · número 2 · págs. 161–169
- Editorial
- Wiley
- Citado
- 183 citas · más que el 99% de estudios similares · 10.8× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 49 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Dementia and Cognitive Impairment Research · Alzheimer's disease research and treatments
- Palabras clave
- omega-3 fatty acids, docosahexaenoic acid, eicosapentaenoic acid, Alzheimer's disease, neuropsychiatric symptoms, APOE ε4, agitation, depression, caregiver burden, activities of daily living, dietary supplementation, acetylcholinesterase inhibitors
- MeSH
- humans, alzheimer disease, phenylcarbamates, galantamine, piperidines, indans, fatty acids, omega-3, apolipoproteins e, cholinesterase inhibitors, treatment outcome, activities of daily living, analysis of variance, statistics, nonparametric, double-blind method, depression, psychiatric status rating scales, genotype, dietary supplements, aged, female, male, rivastigmine, donepezil
10 autores
- Yvonne Freund‐Levi🇸🇪 · autor de correspondenciaKarolinska University Hospital; Karolinska Institutet
- Hans Basun🇸🇪Uppsala University Hospital
- Tommy Cederholm🇸🇪Uppsala University Hospital
- Gerd Faxén Irving🇸🇪Karolinska University Hospital; Karolinska Institutet
- Anita Garlind🇸🇪Karolinska University Hospital; Karolinska Institutet
- Mikaela Grut🇸🇪Danderyds sjukhus
- Inger Vedin🇸🇪Karolinska University Hospital; Karolinska Institutet
- Jan E.W. Palmblad🇸🇪Karolinska University Hospital; Karolinska Institutet
- Lars‐Olof Wahlund🇸🇪Karolinska University Hospital; Karolinska Institutet
- Maria Eriksdotter🇸🇪Karolinska University Hospital; Karolinska Institutet
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Epidemiological and animal studies have suggested that dietary fish or fish oil rich in omega-3 fatty acids (omega3), docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), may have effects in psychiatric and behavioral symptoms in Alzheimer's disease (AD). An association with APOEomega4 carriers and neuropsychiatric symptoms in AD has also been suggested.
Objective
To determine effects of dietary omega3 supplementation to AD patients with mild to moderate disease on psychiatric and behavioral symptoms, daily functions and a possible relation to APOEgenotype.
Methods
Randomized, double-blind, placebo-controlled clinical trial where 204 AD patients (74+/-9 years) with acetylcholine esterase inhibitor treatment and a MMSE>15 points were randomized to daily intake of 1.7 g DHA and 0.6 g EPA (omega3 group) or placebo for 6 months. Then, all received the omega3 supplementation for 6 more months. Neuropsychiatric symptoms were measured with Neuropsychiatric Inventory (NPI) and Montgomery Asberg Depression Scale (MADRS). Caregivers burden and activities of daily living (Disability Assessment for Dementia, DAD) were also assessed.
Results
One hundred and seventy-four patients fulfilled the trial. 72% were APOEomega4 carriers. No significant overall treatment effects on neuropsychiatric symptoms, on activities of daily living or on caregiver's burden were found. However, significant positive treatment effects on the scores in the NPI agitation domain in APOEomega4 carriers (p=0.006) and in MADRS scores in non-APOEomega4 carriers (p=0.005) were found.
Conclusions
Supplementation with omega3 in patients with mild to moderate AD did not result in marked effects on neuropsychiatric symptoms except for possible positive effects on depressive symptoms (assessed by MADRS) in non-APOEomega4 carriers and agitation symptoms (assessed by NPI) in APOEomega4 carriers. ClinicalTrials.gov identifier: NCT00211159
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.